Advertisement

Topics

Latest Top Pharmaceutical Companies in India NewsRSS

22:00 EDT 23rd May 2018 | BioPortfolio

India's Dr. Reddy's Q4 profit falls about 19 pct, misses estimates

Indian generic drugmaker Dr. Reddy's Laboratories Ltd posted an about 19 percent fall in quarterly net profit, missing estimates, hurt by headwinds in the U.S. market. Profit for the quarter ended March 31 came in at 2.72 billion rupees versus 3.38 billion rupees a year earlier, the company said here Net sales fell slightly to 34.46 billion rupees.

Dr. Reddy’s Q4 and FY18 Financial Results

Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2018 under International Financial Reporting Standards (IFRS). Q4 Performance Summary   ...

Carcinoid Syndrome Management Market 2018 - Identify Opportunities...

Global Carcinoid Syndrome Management Market - Key Players Key players profiled in the report are: Novartis International AG Pharmascience Inc. Omega Laboratories Ltd. Teva Pharmaceutical Industries Ltd. Mylan N.V. Ipsen Biopharmaceuticals Inc. Sirtex Medical Limited BTG International Ltd. Wockhardt Ltd. Sun Pharmaceutical Industries Limited Global Carcinoid Syndrome Management Market - Overview Th...

New Survey of Healthcare Professionals Unveils Need for Awareness and Education of Bacterial Vaginosis to Ensure Proper Care and Treatment

National survey reveals need for more discussion regarding risks associated with the most common, but often misunderstood, vaginal infection Healthcare professionals feel current treatments for BV are difficult for patients to adhere to Lupin Pharmaceuticals Inc., the U.S. wholly owned subsidiary of Lupin Limited, dedicated to...

Dr. Reddy's to Release Q4 and Full Year FY18 Results on May 22, 2018

Earnings call slated for May 22, 6:30 PM IST / 9:00 AM EDT Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the Fourth Quarter and Full year ended March 31, 2018 on Tuesday, May 22, 2018 after the Board Meeting. The results will be available on the Company’s website www.drreddys.com. Summary of Events...

Glenmark suspends Ph II clinical trial at Indian site following alleged ‘irregularities’

Glenmark Pharmaceuticals has suspended a Phase II clinical trial at a site in India following media reports that villagers were allegedly âdeceivedâ into participating.

Glenmark suspends Ph II clinical trial following alleged ‘irregularities’ at Indian site

Glenmark Pharmaceuticals has suspended a Phase II clinical trial at a site in India following media reports that villagers were allegedly âdeceivedâ into participating.

Actinium Pharmaceuticals Strengthens Targeted Myeloablation Focused Clinical Development Team with New Hires Including Experienced Bone Marrow Transplant Physician and Drug Developer Vijay Reddy, M.D., Ph.D. as Vice President, Clinical Development

- Dr. Vijay Reddy joins Actinium with over 20 years of bone marrow transplant clinical experience including extensive product development experience at Pharmacyclics, an AbbVie Company, Medimmune and Johnson & Johnson  - Dr. Reddy will be focused on Actinium’s targeted myeloablation programs including the Pivotal Phase 3 SIERRA trial for Iomab-B and the planned Phase 2 Actimab-MDS...

GLOBAL BOTANICAL PLANT DERIVATIVE DRUG MARKET FORECAST 20182026 [Report Updated: 15012018] Prices from USD $2500

KEY FINDINGSThe Global Botanical and plantderivative drug market was estimated to be worth $ 26621 million in 2017. Due to the growing application of these drugs in several diseases, the market is expected to witness a rise in CAGR of 8.58% for the forecast years of 20182026 and is predicted to reach a worth of $53850 million by its end.MARKET INSIGHTSThe global botanical and plantderivative drug ...

Glenmark Pharmaceuticals Limited Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 15022018] Prices from USD $350

Glenmark Pharmaceuticals Limited Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Glenmark Pharmaceuticals Limited Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership tra...

Global and China Ketorolac Market Research by Company, Type Application 20132025 [Report Updated: 06032018] Prices from USD $2000

SummaryMarket Segment as follows:By Type Orange Oil Bergamot Oil Lemon Oil Lime Oil Mandarin Oil Grapefruit OilBy Application Medical Uses Chemistry Uses OthersBy Company Allergan DeepCare Health Cadila FDC Intas Laboratories Gufic Chem Ranbaxy Adley Formulation Neon Laboratories Sun Pharmaceutical Industries Cipla Dallas P

Glenmark Pharmaceuticals Ltd GLENMARK Financial and Strategic SWOT Analysis Review [Report Updated: 09032018] Prices from USD $300

SummaryGlenmark Pharmaceuticals Ltd Glenmark is a pharmaceutical company which focuses on the discovery of new chemical entities NCEs and new biological entities NBEs. The company's formulations business encompasses therapeutic areas such as dermatology, antiinfective, respiratory, cardiac, diabetes, gynecology, central nervous system, and oncology. It also offers a wide range of generic products....

Dr. Reddy’s names Teva vet COO

Ongoing regulatory issues helps downgrade Wockhardt’s ratings

India Ratings has downgraded Wockhardt partly on the back of ongoing remediation at seven manufacturing facilities.

FDA approval spurs launch of Lupin’s generic Clobex Spray

Slayback Pharma Appoints Abhijit Mukherjee as Senior Advisor

Slayback Pharma, LLC (“Slayback”), a privately held pharmaceutical research and development company, announced today the appointment of Abhijit Mukherjee as a Senior Advisor to the Board and Management of Slayback, effective immediately. In this role, Abhijit will advise the company on strategic and operational matters. "There are very few lea...

Dr. Reddy's Laboratories and its U.S. subsidiary Promius Pharma announce the filing of an NDA for its migraine candidate

Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and its subsidiary, Promius Pharma, LLC today announced the filing of New Drug Application (NDA) for its migraine candidate DFN-02 with the U.S. Food and Drug Administration (USFDA). According to Dr. Anil Namboodiripad, Senior Vice President, Proprietary Products and President, ...

Dr. Reddy’s Files NDA for Migraine Treatment

Migraine sufferers could have a new treatment option. India-based Dr. Reddy’s Laboratories and its subsidiary Promius Pharma, LLC filed a NDA with the U.S. FDA for approval of migraine candidate DFN-02.

Insulin biosimilar Semglee gains EC and Australian approval

India-based Biocon and US-based partner Mylan announced on 28 March 2018 that they had received European Commission (EC) and Australian approval for their co-developed insulin glargine biosimilar, Semglee.

Follow-on biologicals deals for Hikma and Lupin

Collaborations are once again the way forward when it comes to biosimilars. Jordan-based drugmaker Hikma Pharmaceuticals (Hikma) made a licensing deal with South Korean biotechnology company Celltrion in December 2017.  In March 2018 Indian generics maker Lupin Pharmaceuticals (Lupin) made an agreement with the Council of Scientific and Industrial Research-National Chemical Laboratory (CSIR-N...

Biosimilar deals for Hikma and Lupin

Collaborations are once again the way forward when it comes to biosimilars. Jordan-based drugmaker Hikma Pharmaceuticals (Hikma) made a licensing deal with South Korean biotechnology company Celltrion in December 2017.  In March 2018 Indian generics maker Lupin Pharmaceuticals (Lupin) made an agreement with the Council of Scientific and Industrial Research-National Chemical Laboratory (CSIR-N...

Cadila Healthcare Ltd CADILAHC Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 15022018] Prices from USD $250

SummaryCadila Healthcare Ltd Cadila is an integrated, global healthcare provider. It discovers, develops, manufactures and markets various healthcare products. The company's product portfolio includes active pharmaceutical ingredients APIs, formulations, wellness and animal health products. Cadila's products find application in the treatment of disease related to gastrointestinal, cardiovascular, ...

Dr. Reddy's Laboratories Announces Senior Leadership Changes

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced a change in the makeup of its senior leadership team. Following a 15-year career with the company, Mr. Abhijit Mukherjee, Chief Operating Officer, will retire on March 31, 2018. Mr. Mukherjee will be succeeded by Mr. Erez Israeli, former President & ...

Mylan, Biocon Receive MAA

Mylan and Biocon announced that their co-developed biosimilar insulin glargine Semglee has received marketing authorization approval from the European Commission following the positive recommendation by the Committee for Medicinal Products for Human Use of European Medicines Agency. Semglee 100 units/mL 3 mL prefilled disposable pen for people with diabetes, is the first biosimilar from Biocon and...

Dr. Reddy's Laboratories Limited Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 18022018] Prices from USD $350

Dr. Reddy's Laboratories Limited Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Dr. Reddy's Laboratories Limited Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership tra...

Advertisement
Quick Search
Advertisement
Advertisement

 

review and buy Top Pharmaceutical Companies in India market research data and corporate reports here